LumineticsCore™ (formerly known as IDx-DR), the first FDA-cleared AI system for the autonomous detection of diabetic retinopathy, is now available to Harmony users in Europe
OAKLAND, NJ and CORALVILLE, IA, October 23, 2018 – Topcon Healthcare Solutions (THS) announced today that it has partnered with IDx (now known as Digital Diagnostics), a privately held AI diagnostics company, to expand the Harmony imaging platform to include LumineticsCore (formerly known as IDx-DR), a state-of-the art AI system that detects diabetic retinopathy in digital fundus images, for its European customers.
LumineticsCore (formerly known as IDx-DR) is the first AI-based diagnostic system with U.S. FDA clearance and a Class IIa CE mark for the autonomous detection of diabetic retinopathy, a complication of diabetes and a leading cause of blindness. In addition to being available as a stand-alone image-analysis solution, LumineticsCore (formerly known as IDx-DR) is now accessible in Europe via Topcon Harmony, THS’ solution for ophthalmic data viewing, archiving, and clinical decision support.
“We are excited to provide Topcon Harmony customers in Europe with even greater value by expanding the platform’s offerings to include LumineticsCore (formerly known as IDx-DR),” said John Trefethen, Vice President of Global Marketing and Product Design at THS. “The Harmony application is designed to provide medical professionals with excellent usability, performance, and easy access to the tools they need to optimize their practice. With LumineticsCore (formerly known as IDx-DR), we are continuing this commitment by providing customers with convenient access to cutting-edge automated image-analysis technology.”
LumineticsCore (formerly known as IDx-DR) analyzes images of the retina for the same signs of disease an ophthalmologist looks for, providing a reliable output for clinical decision-making. To administer the LumineticsCore (formerly known as IDx-DR) exam, clinic staff capture two images per eye with Topcon’s robotic fundus camera and then submit the exams to the LumineticsCore (formerly known as IDx-DR) client via a standard internet connection. In less than a minute, a disease output will populate. The software also provides immediate feedback on image quality to allow for more accurate disease detection and for poor quality images to be retaken while the patient is in the office. The system is currently used in clinical practices across Europe.
“Making LumineticsCore (formerly known as IDx-DR) available via Topcon Harmony will help improve the accuracy and efficiency of diabetic retinopathy screening for Harmony users in Europe,” said Arlette Goddijn, President of IDx Europe. “IDx believes it is important to integrate with large platforms such as Harmony so that more healthcare professionals can leverage artificial intelligence to manage the rapidly growing number of people with diabetes.”
There are more than 58 million people with diabetes in the European region and this number is expected to grow to 71 million by 2040, according to the International Diabetes Federation.